Related references
Note: Only part of the references are listed.COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies
Manuela Di Fusco et al.
EXPERT REVIEW OF VACCINES (2022)
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
Mark W. Tenforde et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States
Mark W. Tenforde et al.
CLINICAL INFECTIOUS DISEASES (2022)
mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients
Jennie H. Kwon et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
Katherine E. Mues et al.
VACCINE (2022)
Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)
Lindsay Kim et al.
CLINICAL INFECTIOUS DISEASES (2021)
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Kailey Hughes et al.
CLINICAL INFECTIOUS DISEASES (2021)
Administration of COVID-19 vaccines in immunocompromised patients
Manica Negahdaripour et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
Peter J. Embi et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study
Parakkal Deepak et al.
ANNALS OF INTERNAL MEDICINE (2021)
Covid-19 Vaccine Effectiveness and the Test-Negative Design
Natalie E. Dean et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
M. G. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021
Shaun J. Grannis et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET, 14 States, March 1-30, 2020
Shikha Garg et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Risk for In-Hospital Complications Associated with COVID-19 and Influenza - Veterans Health Administration, United States, October 1, 2018-May 31, 2020
Jordan Cates et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
Manish Patel et al.
EMERGING INFECTIOUS DISEASES (2020)
Test-Negative Designs Differences and Commonalities with Other Case-Control Studies with Other Patient Controls
Jan P. Vandenbroucke et al.
EPIDEMIOLOGY (2019)
Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness
Sheena G. Sullivan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)
Prevalence of Immunosuppression Among US Adults, 2013
Rafael Harpaz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Validation of a Method to Identify Immunocompromised Patients with Severe Sepsis in Administrative Databases
Jared A. Greenberg et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
The test-negative design for estimating influenza vaccine effectiveness
Michael L. Jackson et al.
VACCINE (2013)
Share Paper
